Cullinan Therapeutics

(NASDAQ) CGEM

Current Price$14.02

Market Cap$880.69M

Since IPO (2021)-52%

5 Year-47%

1 Year+81%

1 Month-1%

Cullinan Therapeutics Financials at a Glance

Market Cap

$880.69M

Revenue (TTM)

$0.00

Net Income (TTM)

$221.04M

EPS (TTM)

$-3.71

P/E Ratio

-3.86

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$14.02

Volume

705,601.862

Open

$14.28

Price

$14.02

Volume

705,601.862

Open

$14.28

Previous Close

$13.98

Daily Range

$13.81 - $14.43

52-Week Range

$5.68 - $16.74

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$14.02

Volume

705,601.862

Open

$14.28

Previous Close

$13.98

Daily Range

$13.81 - $14.43

52-Week Range

$5.68 - $16.74

CGEM News

CGEM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cullinan Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

Nadim Ahmed

Website

www.cullinantherapeutics.com

Headquarters

Cambridge, MA 02142, US

CGEM Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-48%

Return on Capital

-65%

Return on Assets

-55%

Earnings Yield

-25.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$880.69M

Shares Outstanding

61.46M

Volume

705.60K

Avg. Volume

871.67K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$241.65M

EBITDA

$241.34M

Operating Cash Flow

$175.75M

Capital Expenditure

$49.00K

Free Cash Flow

$175.80M

Cash & ST Invst.

$377.90M

Total Debt

$2.68M

Cullinan Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$79.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$880.69M

N/A

Market Cap/Employee

$7.93M

N/A

Employees

111

N/A

Net Income

$49.66M

-2.4%

EBITDA

$53.70M

+2.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$349.50M

+15.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.66M

+236.3%

Short Term Debt

$725.00K

-46.2%

Return on Assets

-54.85%

N/A

Return on Invested Capital

-65.34%

N/A

Free Cash Flow

$46.05M

-6.7%

Operating Cash Flow

$46.05M

-6.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OMEROmeros Corporation

OMEROmeros Corporation$11.96-3.39%

RAPTRAPT Therapeutics, Inc.

RAPTRAPT Therapeutics, Inc.$58.01+0.00%

CBLLCeriBell, Inc.

CBLLCeriBell, Inc.$18.74+3.54%

EHABEnhabit, Inc.

EHABEnhabit, Inc.$13.80+0.07%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.40+4.94%

VREXVarex Imaging Corporation

VREXVarex Imaging Corporation$10.13+0.00%

LABStandard BioTools Inc.

LABStandard BioTools Inc.$1.04-1.89%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

QBTSD-Wave Quantum

QBTSD-Wave Quantum$25.74+0.33%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.59+0.05%

INTCIntel

INTCIntel$118.50-0.00%

INFQInfleqtion

INFQInfleqtion $14.70+0.31%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.72+0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.95+0.01%

FFord Motor Company

FFord Motor Company$13.67+0.03%

Questions About CGEM

What is the current price of Cullinan Therapeutics?

Cullinan Therapeutics is trading at $13.98 per share.

What is the 52-week range for Cullinan Therapeutics?

Over the past 52 weeks, Cullinan Therapeutics has traded between $5.68 and $16.74.

How much debt does Cullinan Therapeutics have?

As of the most recent reporting period, Cullinan Therapeutics reported total debt of $2.38M.

How much cash does Cullinan Therapeutics have on hand?

Cullinan Therapeutics reported $75.08M in cash and cash equivalents in its most recent financial results.

What is Cullinan Therapeutics’s dividend yield?

Cullinan Therapeutics does not currently have a dividend yield.

Cullinan Therapeutics

Cullinan Therapeutics Financials at a Glance

CGEM News

Cullinan (CGEM) Q2 R&D Jumps 68%

Why Shares of Cullinan Oncology Jumped This Week

Why Cullinan Oncology Stock Is Skyrocketing Today

CGEM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cullinan Therapeutics

CGEM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cullinan Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CGEM

What is the current price of Cullinan Therapeutics?

What is the 52-week range for Cullinan Therapeutics?

How much debt does Cullinan Therapeutics have?

How much cash does Cullinan Therapeutics have on hand?

What is Cullinan Therapeutics’s dividend yield?

Premium Investing Services